Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript
01:07pm, Monday, 06'th Mar 2023
Passage Bio, Inc. (NASDAQ:PASG ) Q4 2022 Earnings Conference Call March 6, 2023 8:30 AM ET Company Participants Stuart Henderson - Vice President, Corporate Development & Investor Relations Will Chou
Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects
11:39pm, Tuesday, 28'th Feb 2023
Passage Bio's most advanced gene therapy reported good early Phase 1 data. Over $200 million in cash should provide funding until more data is available.
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
07:00am, Monday, 27'th Feb 2023
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
07:00am, Wednesday, 15'th Feb 2023
– Updated interim data from first six patients in Phase 1/2 Imagine-1 study of PBGM01 for GM1 Gangliosidosis to be shared in oral platform and poster presentations
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
07:30am, Thursday, 03'rd Nov 2022
PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Present at Chardan's 6th Annual Genetic Medicines Conference
07:00am, Monday, 26'th Sep 2022
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system
Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript
10:50am, Saturday, 06'th Aug 2022
Passage Bio, Inc. (NASDAQ:PASG ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Stuart Henderson - VP of Corporate Development and IR Edgar Cale - Interim CEO Simona K
Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
07:00am, Friday, 05'th Aug 2022
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
07:30am, Thursday, 28'th Jul 2022
PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
07:30am, Thursday, 09'th Jun 2022
PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system d
Passage Bio, Inc.'s (PASG) CEO Bruce Goldsmith on Q1 2022 Results - Earnings Call Transcript
02:07pm, Monday, 16'th May 2022
Passage Bio, Inc. (NASDAQ:PASG ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Stuart Henderson - Vice President of Corporate Development and Investor Relations Bruce G
Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
07:00am, Monday, 09'th May 2022
PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system di
2 Stocks Under $3 Insiders Are Aggressively Buying
03:15pm, Friday, 06'th May 2022
US crude oil futures traded higher on Friday. Investors, meanwhile, focused on some notable insider trades.
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (C
Passage Bio to Participate in Upcoming Investor Conferences
07:00am, Monday, 28'th Mar 2022
PHILADELPHIA, March 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system
